What was filed
Aurobindo Pharma told the exchanges it has completed a transaction first flagged across a series of letters dating back to February 2025. On June 25, 2026, the company acquired a 26% equity stake in Swarnaakshu Solar Power Private Limited and simultaneously executed a power purchase agreement to draw solar power from that entity for its own (captive) consumption, under the captive power policy of the Government of Telangana.
How the investment is structured
The company had earlier disclosed a planned investment of up to Rs.10.40 crore for the 26% stake and associated securities. Per the filing, only an initial portion has been deployed so far, with the balance to be paid in stages as the solar project progresses and as Swarnaakshu's funding needs arise. The arrangement pairs an equity holding with a long-term supply agreement, giving Aurobindo a captive source of solar power rather than a purely financial stake.
Why a holder might note it
The disclosure marks the closing of a step Aurobindo had been signalling for over a year. It is a captive renewable-energy arrangement tied to the company's own power consumption, not a change in its core pharmaceutical business. The figures involved are modest relative to the group's scale, and most of the committed capital remains to be deployed over time.